Similar T-cell immune responses induced by group M consensus Env immunogens with wild-type or minimum consensus variable regions

AIDS Research and Human Retroviruses

Volumn 26, Issue 5, 2010, Pages 577-584

  Weaver, E A ^a   Camacho, Z T ^b   Gao, F ^c  

^a MAYO CLINIC   (United States)

^b WESTERN NEW MEXICO UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELLULAR IMMUNITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; EPITOPE MAPPING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS ISOLATION; VIRUS RECOMBINANT; WILD TYPE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CONSENSUS SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES; VACCINES, DNA; VACCINIA VIRUS;

EID: 77952576985     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0258     Document Type: Article

References (50)

1. Allen TM, O'Connor DH, Jing P, et al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-390.
2. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA=MVA vaccine. Vaccine 2002;20:1949-1955.
3. Barouch DH, Kunstman J, Glowczwskie J, et al.: Viral escape from dominant simian immunodeficiency virus epitopespecific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003;77:7367-7375.
4. Barouch DH, Kunstman J, Kuroda MJ, et al.: 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2003;415:335-339.
5. Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokineaugmented DNA vaccination. Science 2000:290:486-492.
6. Bartlett JA, Wasserman SS, Hicks CB, et al.: Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division ofAIDS Treatment Research Initiative.Aids 1998;12:1291-1300.
7. Binley JM, Wrin Korber B, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:3232-3252.
8. Borrow P, Lewicki H, Wei X, et al.: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
9. Braibant M, Brunet S, Costagliola D, et al.: Antibodies to conserved epitopes of the HIV-1 envelope in sera from longterm non-progressors: prevalence and association with neutralizing activity. Aids 2006;20:1923-1930.
10. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
11. Castro BA, Homsy J, Lennette E: HIV-1 expression in chimpanzees can be activated by CD8+ cell depletion or CMV infection. Clin Immunol Immunopathol 1992;65:227-233.
12. Catanzaro AT, Roederer M, Koup RA, et al.: Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007;25:4085-4092.
13. Chakrabarti S, Sisler JR, Moss BB, et al.: Compact, synthetic, vaccinia virus early=late promoter for protein expression. Biotechniques 1997;23:1094-1097.
14. Cho MW, Kim YB, Lee MK: Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian=human immunodeficiency virus infection in pigtailed macaques. J Virol 2001;75:2224-2234.
15. De Groot AS, Rivera DS, McMurry JA, et al.: Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 2008;26:3059-3071.
16. Ellenberger DL, Li B, Lupo LD, et al.: Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 2002;302:155-163.
17. Ferrari G, Humphrey W, McElrath MJ, et al.: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 1997;94:1396-1401.
18. Ferrari G, Kostyu DD, Cox J, et al.: Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 2000;16:1433-1443.
19. Gao F, Korber BT, Weaver E, et al: Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004;3:S161-S618.
20. Gao F, Weaver EA, Lu Z, et al.: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005;79: 1154-1163.
21. Gauduin MC, Parren PW, Weir R, et al.: Passive immunization with a human monoclonal antibody protects hu-PBLSCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3:1389-1393.
22. Jin X, Bauer DE, Tuttleton SE, et al.: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189: 991-998.
23. Kong WP, Huang Y, Yang ZY, et al.: Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003;77:12764-12772.
24. Kong WP, Wu L, Wallstrom TC, et al.: Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009;83: 2201-2215.
25. Korber B, Muldoon M, Theiler J: Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288:1789-1796.
26. Leitner T, et al.: HIV sequence compendium 2003. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 2004).
27. Letvin NL, Montefiori DC, Yasutomi Y, et al.: Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997;94:9378-9383.
28. Letvin NL, Schmitz JE, Jordan HL, et al.: Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol Rev 1999;170:127-134.
29. Liao HX, Sutherland LL, Xia SM, et al.: A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006;353:268-282.
30. Lifson JD, Rossio JL, Piatak M Jr, et al.: Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001;75:10187-10199.
31. Machuca A, Tang S, Hu J, et al.: Increased genetic diversity and intersubtype recombinants of HIV-1 in blood donors from urban Cameroon. J Acquir Immune Defic Syndr 2007; 45:361-363.
32. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1=SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
33. Matano T, Shibata R, Siemon C, et al.: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian=human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998;72:164-169.
34. Metzner KJ, Jin X, Lee FV, et al.: Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med 2000;191:1921-1931.
35. Moore JP, Cao Y, Conley AJ, et al.: Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr 1994;7:332-1229
36. Munoz-Nieto M, Perez-Alvarez L,Thomson M, et al.: IV type 1 intersubtype recombinants during the evolution of a dual infection with subtypes B and G. AIDS Res Hum Retroviruses 2008;4:337-343.
37. Nickle DC, et al: Consensus and ancestral state HIV vaccines (Letter). Science 2003;24:299.
38. Novitsky V, Smith UR, Gilbert P, et al: Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol 2002; 76:5435-5451.
39. Peyerl FW, Barouch DH, Yeh WW, et al.: Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol 2003; 77:12572-12578.
40. Santra S, Korber BT, Muldoon M, et al.: A centralized genebased HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 2008;105:89-94.
41. Seaman MS, Xu L, Beaudry K, et al.: Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005;79:2956-2963.
42. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency- virus immunity. Nature 2002;415:331-335.
43. Sreepian A, Srisurapanon S, Horthongkham N, et al.: Conserved neutralizing epitopes of HIV type 1 CRF01-AE against primary isolates in long-term nonprogressors. AIDS Res Hum Retroviruses 2004;20:531-542.
44. Trkola A, Pomales AB, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
45. UNAIDS=WHO. 2008 Report on the global AIDS epidemic. UNAIDS=WHO, 2008.
46. Veazey RS, Shattock RJ, Pope M, et al: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9: 34-36.
47. Weaver EA, Lu Z, Camacho ZT, et al.: B-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 2006;80:6745-6756.
48. Zwick MB, Bonnycastle LL, Menendez A, et al.: Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol 2001;75:6692-6699
49. Zwick MB, Labrijn AF, Wang W, et al.: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2002;75:10892-10905.
50. Zwick MB, Wang M, Poignard P, et al.: Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001;75:12198-12208. (Pubitemid 33115893)